Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
126 hedge funds and large institutions have $408M invested in Mersana Therapeutics in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 19 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 36
26% more capital invested
Capital invested by funds: $324M → $408M (+$84.4M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.25% less ownership
Funds ownership: 3.89% → 3.64% (-0.25%)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 129 → 126 (-3)
93% less call options, than puts
Call options by funds: $19K | Put options by funds: $257K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$15.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$11.9M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$8.06M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.88M |
| 5 |
BlackRock
New York
|
+$4.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$4.29M |
| 2 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$4.21M |
| 3 |
Two Sigma Investments
New York
|
-$3.1M |
| 4 |
RCP
Rho Capital Partners
New York
|
-$3M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.89M |
MRSN Hedge Fund Activity: Q2 2022 in Review
126 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2022, worth a combined $408M — up 26% from $324M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MRSN and 18 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 51 added.
The largest buyer was OrbiMed, adding an estimated $15.9M. The largest seller was Bank of Montreal, cutting an estimated $4.29M.
- 126 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2022, down from 129 in Q1 2022.
- Funds reported $408M of Mersana Therapeutics stock for Q2 2022, up 26% quarter-over-quarter.
- 18 funds opened new Mersana Therapeutics positions in Q2 2022 and 19 closed out, a net change of -1 holder.
- The largest Mersana Therapeutics buyer in Q2 2022 was OrbiMed, an estimated $15.9M added.
- The largest Mersana Therapeutics seller in Q2 2022 was Bank of Montreal, an estimated $4.29M sold.
Based on aggregated 13F filings for Q2 2022.